Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 5 | 2025 | 1126 | 1.310 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2025 | 256 | 1.280 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 5 | 2025 | 348 | 1.120 |
Why?
|
| Vaping | 1 | 2025 | 63 | 0.830 |
Why?
|
| Hypervitaminosis A | 1 | 2022 | 1 | 0.750 |
Why?
|
| Intracranial Hypertension | 1 | 2022 | 42 | 0.700 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 2024 | 395 | 0.680 |
Why?
|
| Premature Birth | 1 | 2024 | 365 | 0.660 |
Why?
|
| Respiratory Tract Fistula | 1 | 2019 | 7 | 0.620 |
Why?
|
| Cutaneous Fistula | 1 | 2019 | 14 | 0.620 |
Why?
|
| Tracheal Diseases | 1 | 2019 | 15 | 0.620 |
Why?
|
| Airway Extubation | 1 | 2019 | 60 | 0.580 |
Why?
|
| Tracheostomy | 1 | 2019 | 140 | 0.540 |
Why?
|
| Metabolomics | 1 | 2020 | 704 | 0.440 |
Why?
|
| Benzodioxoles | 2 | 2025 | 128 | 0.360 |
Why?
|
| Quinolones | 2 | 2025 | 147 | 0.350 |
Why?
|
| Macrophages | 4 | 2025 | 1561 | 0.350 |
Why?
|
| Aminophenols | 2 | 2025 | 170 | 0.350 |
Why?
|
| Indoles | 2 | 2025 | 429 | 0.320 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2797 | 0.260 |
Why?
|
| Respiratory Therapy | 1 | 2024 | 25 | 0.220 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2024 | 90 | 0.200 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2025 | 105 | 0.200 |
Why?
|
| Pyrrolidines | 1 | 2022 | 90 | 0.180 |
Why?
|
| Burkholderia cenocepacia | 1 | 2020 | 3 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2022 | 358 | 0.170 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 117 | 0.160 |
Why?
|
| Tracheotomy | 1 | 2019 | 25 | 0.150 |
Why?
|
| Tracheobronchomalacia | 1 | 2019 | 15 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2020 | 388 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2025 | 1110 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2022 | 443 | 0.140 |
Why?
|
| Device Removal | 1 | 2019 | 140 | 0.140 |
Why?
|
| Pyridines | 1 | 2022 | 510 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2022 | 434 | 0.140 |
Why?
|
| Propofol | 1 | 2018 | 89 | 0.130 |
Why?
|
| Cytokines | 1 | 2025 | 2098 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 214 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 531 | 0.120 |
Why?
|
| Infant | 2 | 2020 | 9818 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3588 | 0.110 |
Why?
|
| Humans | 10 | 2025 | 141187 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2020 | 11457 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2024 | 6275 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2020 | 1330 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2018 | 582 | 0.100 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 112 | 0.100 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 108 | 0.090 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 412 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 182 | 0.090 |
Why?
|
| Bleomycin | 1 | 2013 | 248 | 0.090 |
Why?
|
| Lung | 1 | 2024 | 4134 | 0.090 |
Why?
|
| Child | 3 | 2020 | 22308 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2020 | 5799 | 0.080 |
Why?
|
| Colorado | 1 | 2019 | 4610 | 0.070 |
Why?
|
| Young Adult | 3 | 2020 | 13673 | 0.070 |
Why?
|
| Time Factors | 1 | 2019 | 6956 | 0.070 |
Why?
|
| Female | 6 | 2020 | 75515 | 0.070 |
Why?
|
| Male | 5 | 2020 | 69783 | 0.070 |
Why?
|
| Brain | 1 | 2018 | 2858 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3709 | 0.060 |
Why?
|
| Risk Factors | 1 | 2019 | 10438 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2019 | 16273 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 22007 | 0.050 |
Why?
|
| Chloride Channel Agonists | 1 | 2023 | 95 | 0.050 |
Why?
|
| Chlorides | 1 | 2023 | 138 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 1936 | 0.040 |
Why?
|
| Cysteamine | 1 | 2020 | 9 | 0.040 |
Why?
|
| Gene Editing | 1 | 2020 | 86 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 150 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 358 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1040 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 273 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 209 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2018 | 664 | 0.020 |
Why?
|
| Hyperoxia | 1 | 2013 | 91 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 129 | 0.020 |
Why?
|
| Mutation | 1 | 2023 | 4013 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2013 | 341 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2013 | 863 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 1234 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 410 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2520 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 39177 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 1114 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2504 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2013 | 4208 | 0.010 |
Why?
|
| Rats | 1 | 2013 | 5629 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 11120 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 24574 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 34434 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 37657 | 0.010 |
Why?
|